期刊文献+

活血通脉灵治疗非创伤性股骨头缺血坏死的疗效研究 被引量:4

Therapeutic Effect of Huoxuetongmailing on Non-traumatic Avascular Necrosis of Femoral Head
下载PDF
导出
摘要 目的对活血通脉灵治疗非创伤性股骨头缺血坏死的疗效进行研究。方法方便选取2014年1月—2016年6月之间该院收治的FicatⅡ期非创伤性股骨头缺血坏死患者44例作为研究对象,随机抽取19例设为观察组,25例设为对照组,对照组患者予关节镜辅助下行髓芯减压+异体骨植骨术,而观察组在对照组基础上配合中药活血通脉灵治疗,观察并对比两组患者的治疗效果。结果 44例均获得随访,随访时间8~12个月,观察组患者治疗有效率达到94.73%,高于对照组患者的88.00%,观察组患者生活质量评分高于对照组患者,并且组间对比差异有统计学意义(P<0.05)。结论对非创伤性股骨头缺血坏死患者采用关节镜辅助下进行髓芯减压+异体骨植骨术,配合中药活血通脉灵治疗,能够提高患者的治疗有效率、生活质量,具有临床推广价值。 Objective This paper tries to study the curative effect of Huoxuetongmailing on non-traumatic avascular necrosis of femoral head. Methods 44 patients with Ficat II non-traumatic avascular necrosis of femoral head from January 2014 to June 2016 were convenient selec in this study. 19 cases were randomly selected as the observation group, 25 cases as the control group, the control group of patients under the arthroscopic adopted core decompression and allogeneic bone grafting,and the observation group on the basis of the control group adopted traditional Chinese medicine Huoxuetongling treatment,the therapeutic effect of two groups were observed and compared. Results 44 cases were followed up for 8-12 months. The effective rate of treatment was 94.73% in the observation group, which was higher than that in the control group of 88.00%.The quality of life of the observation group was higher than that of the control group, the difference was statistically significant(P〈0.05). Conclusion The patients with non-traumatic avascular necrosis of the femoral head underwent endoscopic decompression and allogeneic bone grafting can improve the treatment efficiency and quality of life, therefore it is worth promotion and application.
作者 梁辉
出处 《中外医疗》 2017年第33期183-185,共3页 China & Foreign Medical Treatment
关键词 活血通脉灵 非创伤性股骨头缺血坏死 FicatⅡ期 髓芯减压 Huoxuetongmailing Non-traumatic avascular necrosis of the femoral head Ficat Ⅱ Core decompression
  • 相关文献

参考文献6

二级参考文献38

  • 1KIM ES, HIRSH V, MOK T,et al. Gefitinib versus docetaxel in previously treated on-small cell lung cancer (INTEREST): a randomised phase Ⅲ trial [ J ]. Lancet, 2008, 372 ( 9652 ) : 1809 - 1818.
  • 2SHI Y, ZHANG L, LIU X, et al. Icotinib versus gefitinib in pre- viously treated advanced non-small-cell lung cancer (ICOGEN) : a randomised, double-blind phase 3 non-inferiority trial [ J ]. Lancet Oncol,2013,14 (10) :953 - 961.
  • 3SHEPHERD FA ,RODRIGUES PEREIRA J, CIULEANU T, et al. Erlotinib in previously treated non-small cell lung cancer[ J]. N Engl J Med,2005,353(2) : 123 - 132.
  • 4LEE DH, PARK K, KIM JH,et al. Randomized Phase Ⅲ trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy [ J ]. Clin Cancer Res , 2010 ,16 ( 4 ) :1307 - 1314.
  • 5WANG J,CHEN K, BAI H, et al. Chemotherapy influence EG- FR mutation status for Chinese patients with regionally advanced non-small cell lung cancer [ J ]. J Clin Oncol, 2011,29 (suppl) : abstr 7031.
  • 6TARON M, ICHINOSE Y, ROSELL R, et al. Activating muta- tions in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas [ J ]. Clin Cancer Res, 2005,11(15) :5878 -5885.
  • 7GANDARA DR, GRIMMINGER P, MACK PC, et al. Associa- tion of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer[ J]. J Thorac 0ncol,2010,5 ( 12 ) : 1933 - 1938.
  • 8MOK TS, WU YL, THONGPRASERT S, et al. Gefitinib or car- boplatin-paclitaxel in pulmonary adenocarcinoma[ J ] . N Engl J Med, 2009, 361 (10) :947 - 957.
  • 9MAEMONDO M, INOUE A, KOBAYASHI K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR [ J]. N Engl J Med,2010,362(25) :2380 -2388.
  • 10ZHOU C, WU YL, CHEN G, et al. Erlotinib versus chemother- apy as first-line treatment for patients with advanced EGFR muta- tion-positive non-small-cell lung cancer (OPTIMAL, CTONG- 0802): a muhicentre, open-label, randomised, phase 3 study [J]. Lancet Oncol,2011,2(8) :735 -742.

共引文献70

同被引文献42

引证文献4

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部